Following is a comprehensive listing of Dr. Spangle's scientific publications:
Lee M, Geitgey DK, Hamilton JAG, Boss JM, Scharer CD, Spangle JM, Haynes KA, Henry CJ. Front Cell Dev Biol. 2022. Adipocyte-mediated epigenomic instability in human T-ALL cells is cytotoxic and phenocopied by epigenetic-modifying drugs. 10:909557. doi: 10.3389/fcell.2022.909557.
McSwain LF, Parwani KK, Shahab SW, Hambardzumyan D, MacDonald TJ, Spangle JM, Kenney AM. Front Oncol. 2022. Medulloblastoma and the DNA Damage Response. 12:903830. doi: 10.3389/fonc.2022.903830.
Tang KC, Cao J, Boatner LM, Li L, Farhi J, Houk KN, Spangle J, Backus KM, Raj M. Angew Chem Int Ed Engl. 2022. Tunable Amine-Reactive Electrophiles for Selective Profiling of Lysine. 61(5):e202112107. doi: 10.1002/anie.202112107.
9. Spangle JM, Von T, Pavlick DC, Khotimsky A, Zhao JJ, Roberts TM. 2020. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition. DOI: 10.1073/pnas.2000060117.
8. Thorpe LM*, Spangle JM*, Ohlson CE, Cheng H, Roberts TM, Cantley LC, and Zhao JJ. 2017. PI3K-p110a mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85a. 114(27):7095-7100 (*authors contributed equally).
7. Spangle JM and Roberts TM. 2017. Epigenetic regulation of RTK signaling. Journal of Molecular Medicine. 95(8):791-798.
6. Spangle JM*, Roberts TM, and Zhao JJ*. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. 2017. BBA Reviews in Cancer. 1868(1):123-131. (*, co-corresponding authors).
5. Spangle JM, Dreijerink KM, Groner AC, Cheng H, Ohlson C, Reyes J, Lin CY, Bradner J, Zhao JJ, Roberts TM, and Brown M. 2016. PI3K/AKT signaling regulates H3K4 methylation in breast cancer. Cell Reports. 15(12):2692-704.
4. Wang Q*, Liu P*, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. 2015. PI3K-p110a mediates resistance to HER2-targeted therapies in HER2+, PTEN-deficient breast cancers. Doi:10.1038/onco.2015.406. (*, authors contributed equally)
3. Spangle JM, and Munger K. 2013. The HPV16 E6 oncoprotein amplifies receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLOS Pathogens. 9(3):e1003237.
2. Spangle JM, Ghosh-Choudhury N, Munger K. 2012. Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. Virol. 86(14):7466-72.
1. Spangle JM, and Munger K. 2010. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 and increases protein synthesis. Virol. 84:9398-9407.